Meeting
2021 ASCO Annual Meeting
CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.
Authors
Jordan Gauthier
Fred Hutchinson Cancer Research Center, Seattle, WA
Jordan Gauthier , Aisling Cearley , Paula Perkins , Angela Kirk , Mazyar Shadman , Staci Williamson , Jessie Myers , Andy I. Chen , Sarah Nagle , Brandon M. Hayes-Lattin , Levanto Gershon Schachter , David G. Maloney , Cameron John Turtle , Mohamed Lotfy Sorror , Richard T. Maziarz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7532)
DOI
10.1200/JCO.2021.39.15_suppl.7532
Abstract #
7532
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.
First Author: Armin Ghobadi
Poster
2018 ASCO Annual Meeting
Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma.
First Author: Jordan Gauthier
Poster
2023 ASCO Annual Meeting
Impact of fludarabine exposure on the depth and duration of lymphopenia and CAR T-cell outcomes.
First Author: Keagan Lipak
Poster
2023 ASCO Annual Meeting
Effect of bispecific B7H3 x CD19 CAR T cells on host CD19 expression and CAR T cell engraftment.
First Author: Navin R. Pinto